FDA Approves Component of Chemotherapy Regimen for ALL and LBL

On June 30, 2021, the U.S. Food and Drug Administration (FDA) approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a multi-agent chemotherapy regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients who are allergic to the E. coli-derived asparaginase products used most commonly for treatment.

Read the FDA announcement.

Read the Jazz Pharmaceuticals announcement.

Posted 7/1/2021